Thus, the FSHD Lymphoblast score may be a superior biomarker to late DUX4 target gene expression biomarkers in detection of the early stages of FSHD pathological inflammation, at a time when it is possibly reversible. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.